Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc at Evercore ISI HealthCONx Virtual Conference Transcript

Nov 30, 2021 / 06:25PM GMT
Release Date Price: R$22.26 (-0.49%)
Maneka Mirchandaney
Evercore ISI Institutional Equities, Research Division - Analyst

Awesome. Hi, everyone. This is Maneka Mirchandaney from the Evercore ISI biotech team. Very pleased to be here with Sarepta. I have some important updates coming up early next year and beyond. So from the team we've got Doug Ingram, who's President and CEO; and Ian Estepan as well, who is the CFO. Thanks for joining us, Doug. I want to turn it over to you just to give us a quick snapshot of where Sarepta is right now.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Sure. And I'll be brief given the short amount of time we have. Look, we are exiting 2021 into 2022 with the wind at our backs. Things have gone from an execution perspective this year, very, very well. You'll remember back in February, we had our third approval, which is for AMONDYS. Revenue has done brilliantly. We had our 20th straight quarter of strong growth. We've had to raise our guidance over the course of this year twice. We'll now do between $605 million and $615 million this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot